Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial

BACKGROUND: Evidence increasingly points to the importance of chronic hypoxia in the tubulointerstitium as a final common pathway to end-stage renal disease (ESRD). Beraprost sodium (BPS) is an orally active prostacyclin (PGI(2)) analogue demonstrating prevention of the progression of chronic kidney...

Descripción completa

Detalles Bibliográficos
Autores principales: Koyama, Akio, Fujita, Toshiro, Gejyo, Fumitake, Origasa, Hideki, Isono, Masanao, Kurumatani, Hajimu, Okada, Kiyonobu, Kanoh, Hiroyuki, Kiriyama, Takashi, Yamada, Shunsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608181/
https://www.ncbi.nlm.nih.gov/pubmed/26475266
http://dx.doi.org/10.1186/s12882-015-0130-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608181/
https://www.ncbi.nlm.nih.gov/pubmed/26475266
http://dx.doi.org/10.1186/s12882-015-0130-5

Ejemplares similares